These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32267111)

  • 1. [Extended indications for antidiabetic agents with cardio-renal protection in updated international recommendations for themanagement of at risk patients with type2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2020 Apr; 75(4):233-239. PubMed ID: 32267111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Dec; 73(12):629-633. PubMed ID: 30570234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
    Diabetes Care; 2020 Feb; 43(2):487-493. PubMed ID: 31857443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Zealand may finally get funded access to diabetes drugs which reduce cardiovascular events and progression of kidney disease: an audit of proposed PHARMAC criteria compared with international guidelines.
    Vitz M; Moss B; Ward H; Soma P; Isichei-Kizito J; Hall R; Krebs J
    N Z Med J; 2020 Oct; 133(1523):76-86. PubMed ID: 33032305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.
    Bertoluci MC; Salles JEN; Silva-Nunes J; Pedrosa HC; Moreira RO; da Silva Duarte RMC; da Costa Carvalho DM; Trujilho FR; Dos Santos Raposo JFC; Parente EB; Valente F; de Moura FF; Hohl A; Melo M; Araujo FGP; de Araújo Principe RMMC; Kupfer R; Costa E Forti A; Valerio CM; Ferreira HJ; Duarte JMS; Saraiva JFK; Rodacki M; Castelo MHCG; Monteiro MP; Branco PQ; de Matos PMP; de Melo Pereira de Magalhães PC; Betti RTB; Réa RR; Trujilho TDG; Pinto LCF; Leitão CB
    Diabetol Metab Syndr; 2020; 12():45. PubMed ID: 32489427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.
    Chang HY; Su YW; Feng AN; Fong MC; Huang KC; Chong E; Chen KC; Yin WH
    ESC Heart Fail; 2020 Apr; 7(2):604-615. PubMed ID: 31995274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
    Rangaswami J; Bhalla V; de Boer IH; Staruschenko A; Sharp JA; Singh RR; Lo KB; Tuttle K; Vaduganathan M; Ventura H; McCullough PA;
    Circulation; 2020 Oct; 142(17):e265-e286. PubMed ID: 32981345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2020 Aug; 16(703):1478-1482. PubMed ID: 32852167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view.
    Scheen AJ
    Diabetes Res Clin Pract; 2020 Jan; 159():107726. PubMed ID: 31108136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.